ASPO Abstracts
Perceptions of Multi-Cancer Early Detection in Primary Care: A Scoping Review
Category: Early Detection & Risk Prediction
Conference Year: 2022
Abstract Body:
Purpose. New cancer screening modalities are being developed, including liquid biopsy and multi-cancer early detection (MCED) tests. Research is needed to understand the factors associated with patient and provider receptivity to MCED testing in the primary care setting.Methods. We conducted a scoping review of the research databases PubMed, Ovid, and Scopus to identify studies of patient and provider perceptions related to liquid biopsy and MCED in cancer screening. We included articles published between January 2000 and June 2021 and used key words such as "multi-cancer screening,"¬ù "liquid biopsy,"¬ù "multi-cancer early detection,"¬ù "MCED,"¬ù and "multi-analyte testing."¬ù Two reviewers excluded duplicates and excluded articles that did not focus on the defined topic areas. Differences were adjudicated through discussions involving a third reviewer.Results. The research team identified 208 articles, excluded 201 that did not address patient and provider perceptions of liquid biopsy and/or MCED testing, and retained 7 for final review. We found that none of the articles reported on provider perceptions of liquid biopsy and/or MCED testing. Among the articles retained for final review, 5 focused on patient perceptions about test use in colorectal cancer screening and 2 reported on patient views related to cancer screening. Patients included in the studies were primarily 50-80 years of age and were at average risk for cancer. Overall, we found that patients were very receptive to blood-based cancer screening. Reasons cited included familiarity with having a blood test, the perceived safety of having a blood test, the lack of a need for preparatory activities prior to testing, and the non-invasiveness of such testing. In one study, patient preference for liquid biopsy or MCED cancer screening was comparable among whites and African American, after controlling for sociodemographic background.Conclusions. Liquid biopsy and MCED tests are new technologies that are likely to impact cancer screening. Patients' perceptions about this type of testing are favorable. An important area of further research is an assessment of provider perceptions about liquid biopsy and MCED screening and patient receptivity to such testing, compared to other recommended screening modalities.
Keywords: multi-cancer early detection, liquid biopsy, patient and provider preferences of cancer screening